Skip to content

Scott L Burrows, Chief Financial Officer at Spyre Therapeutics, sold SYRE on Sep 1, 2026

Data as of Oct 16

▼ SELL$17.8K200 shares at $89.04Scott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.
Watch SYRE
Traded
Sep 1, 2026
Disclosed
Sep 3, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Scott L Burrows, Chief Financial Officer at Spyre Therapeutics, sold SYRE on Sep 1, 2026TRADEDDISCLOSED
SYRESimilar stocks (XLV — its sector index fund), rebased to SYRE's price on the disclosure day
SYRE since disclosure
−8.4%
after the sale
Similar stocks (XLV) since disclosure
+2.0%
XLV — its sector index fund

Change in closing price from Sep 3, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$1.6Mdisclosed Sep 3 · filed 1 day after the trade
  2. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$77.6Kdisclosed Sep 3 · filed 2 days after the trade
  3. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$382Kdisclosed Sep 3 · filed 2 days after the trade
  4. ▼ SELLScott L Burrows Chief Financial OfficerSYRE Spyre Therapeutics, Inc.$177Kdisclosed Sep 3 · filed 2 days after the trade

See every trade on SYRE →